Allergan Funding SCS, headquartered in Luxembourg, was founded to facilitate financing for its parent company, Allergan, in the healthcare sector. The company focuses primarily on raising capital through bond issuance to support Allergan's various business operations and product developments.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| AGN 2.13% 2029-06-01 EURAllergan Funding SCS. | Luxembourg | 2029-06-01 | 2.125 | 3.65 |
| AGN 2.63% 2028-11-15 EURAllergan Funding SCS. | Luxembourg | 2028-11-15 | 2.625 | 3.58 |
| AGN 3.80% 2025-03-15 USDAllergan Funding SCS. | Luxembourg | 2025-03-15 | 3.800 | 3.77 |
| AGN 4.55% 2035-03-15 USDAllergan Funding SCS. | Luxembourg | 2035-03-15 | 4.550 | 5.75 |
| AGN 4.75% 2045-03-15 USDAllergan Funding SCS. | Luxembourg | 2045-03-15 | 4.750 | 7.56 |
| AGN 4.85% 2044-06-15 USDAllergan Funding SCS. | Luxembourg | 2044-06-15 | 4.850 | 7.14 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Allergan Funding SCS has issued a variety of bonds, with its first issuance dating back to 2013. Notably, the company had a significant bond offering in 2020 that was used to finance Allergan's acquisition by AbbVie, showcasing the issuer's role in major corporate maneuvers. Currently, the yields on its bonds remain competitive, reflecting a robust financial position in relation to industry benchmarks, while specific features like call options have made its offerings particularly appealing to investors.